Published in Gastroenterology on January 01, 2004
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol (2007) 2.17
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci (2007) 1.96
Inflammatory bowel disease: past, present, and future. J Gastroenterol (2007) 1.83
Review article: multiple myeloma and inflammatory bowel disease. Dig Dis Sci (2007) 1.64
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Ablation of tumor necrosis factor is associated with decreased inflammation and alterations of the microbiota in a mouse model of inflammatory bowel disease. PLoS One (2015) 1.47
The safety of infliximab infusions in the community setting. Can J Gastroenterol (2010) 1.39
Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc (2009) 1.38
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis. Immunology (2006) 1.34
The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 1.33
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2005) 1.25
Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol (2009) 1.19
Emerging treatments for complex perianal fistula in Crohn's disease. World J Gastroenterol (2009) 1.15
Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica (2011) 1.13
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) (2010) 1.10
Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol (2010) 1.09
Pulmonary manifestations of Crohn's disease. World J Gastroenterol (2014) 1.07
Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol (2006) 1.06
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol (2009) 1.06
Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis (2014) 1.05
Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.03
Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.00
Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol (2011) 1.00
Biologics in inflammatory bowel disease: how much progress have we made? Gut (2004) 0.99
Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol (2013) 0.99
Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut (2004) 0.97
Pneumococci: immunology of the innate host response. Respirology (2010) 0.95
Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol (2015) 0.95
Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci (2012) 0.92
Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. MedGenMed (2005) 0.92
Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol (2014) 0.92
Interstitial lung disease: progress and problems. Postgrad Med J (2006) 0.91
Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2005) 0.91
Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis (2005) 0.91
Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci (2014) 0.91
Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol (2014) 0.90
Crohn's disease as an immunodeficiency. Expert Rev Clin Immunol (2010) 0.89
Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci (2007) 0.88
The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models. Saudi J Gastroenterol (2016) 0.88
Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease. Gut (2006) 0.88
Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis (2013) 0.88
Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion (2009) 0.87
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient (2013) 0.87
Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol (2010) 0.86
Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol (2009) 0.86
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk (2012) 0.86
Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr (2010) 0.86
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol (2011) 0.85
Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol (2012) 0.85
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.85
Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol (2010) 0.85
Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol (2013) 0.84
A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. Gastroenterol Hepatol (N Y) (2007) 0.83
Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease. Dig Dis Sci (2007) 0.83
Recent developments in the surgical management of perianal fistula for Crohn's disease. Ann Gastroenterol (2014) 0.83
Infliximab therapy in pediatric Crohn's disease: a review. Clin Exp Gastroenterol (2010) 0.83
Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc (2011) 0.82
Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut (2007) 0.82
Preoperative optimization of Crohn's disease. Clin Colon Rectal Surg (2007) 0.81
Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci (2007) 0.81
Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci (2010) 0.81
Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol (2007) 0.81
Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. World J Gastroenterol (2012) 0.80
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics (2009) 0.80
Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.80
T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary. J Hematop (2009) 0.80
Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol (2005) 0.80
Mucinous carcinoma in Crohn's disease originating in a fistulous tract. World J Gastrointest Oncol (2010) 0.80
Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer (2008) 0.80
Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol (2011) 0.79
Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol (2011) 0.78
Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis (2015) 0.78
Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol (2011) 0.78
Current therapy of pediatric Crohn's disease. World J Gastrointest Pathophysiol (2015) 0.78
Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag (2007) 0.78
Newer Therapies for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2004) 0.77
Preventing infective complications in inflammatory bowel disease. World J Gastroenterol (2014) 0.77
TNF-α inhibitors: are they carcinogenic? Drug Healthc Patient Saf (2010) 0.77
Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis (2010) 0.77
Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol (2008) 0.77
Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. Core Evid (2008) 0.76
Medical management of Crohn's disease. Clin Colon Rectal Surg (2007) 0.76
Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2016) 0.76
Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut (2005) 0.76
Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany. Int J Colorectal Dis (2004) 0.76
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group. Gastroenterol Hepatol (N Y) (2008) 0.75
Prolonged fever after Infliximab infusion. World J Gastrointest Pharmacol Ther (2012) 0.75
Ischaemic/reperfusion injury: Role of infliximab. World J Transplant (2012) 0.75
Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy. Case Rep Pulmonol (2013) 0.75
Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study. Neural Regen Res (2012) 0.75
A rare case of supraventricular tachycardia induced by Infliximab: a case report. Cases J (2009) 0.75
Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α. Int Arch Med (2012) 0.75
Cologastric fistula with a foreign body in a patient with Crohn's disease. Yale J Biol Med (2010) 0.75
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Crohn's disease. Lancet (2012) 4.42
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
Factors affecting the durability of primary total knee prostheses. J Bone Joint Surg Am (2003) 3.44
Incidental findings in imaging research: evaluating incidence, benefit, and burden. Arch Intern Med (2010) 3.40
Ulcerative colitis. Lancet (2012) 3.38
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol (2008) 3.30
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28
Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: factors affecting survivorship of acetabular and femoral components. J Bone Joint Surg Am (2002) 3.24
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol (2007) 2.82
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Effect of femoral head diameter and operative approach on risk of dislocation after primary total hip arthroplasty. J Bone Joint Surg Am (2005) 2.77
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology (2007) 2.76
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology (2005) 2.64
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis (2010) 2.54
Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int (2010) 2.51
Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol (2003) 2.47
Effect of magnetic vs sham-magnetic insoles on nonspecific foot pain in the workplace: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc (2005) 2.46
Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol (2013) 2.39
Complications of diagnostic cerebral angiography: evaluation of 19,826 consecutive patients. Radiology (2007) 2.38
Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am (2002) 2.37
The cumulative long-term risk of dislocation after primary Charnley total hip arthroplasty. J Bone Joint Surg Am (2004) 2.36
Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology (2003) 2.35
Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg (2007) 2.35
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology (2006) 2.34
Solitary fibrous tumors of the pleura: results of surgical treatment and long-term prognosis. J Thorac Cardiovasc Surg (2009) 2.33
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30